Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing next-generation oral and IV antibiotics, has announced its plans to release second quarter 2024 financial results on August 14, 2024, before the U.S. financial markets open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
Investors and interested parties can access the call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and using the Access Code 775539. A pre-registration option is available. The audio webcast will be accessible under the "Financials & Filings" section of Iterum's website at www.iterumtx.com following the call.
Iterum Therapeutics plc (Nasdaq: ITRM), un'azienda farmaceutica in fase clinica che sviluppa antibiotici orali e IV di nuova generazione, ha annunciato i suoi piani per rilasciare i risultati finanziari del secondo trimestre 2024 il 14 agosto 2024, prima dell'apertura dei mercati finanziari statunitensi. L'azienda ospiterà una conferenza telefonica alle 8:30 a.m. ET nello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale.
Gli investitori e le parti interessate possono accedere alla chiamata componendo il numero 833-470-1428 (nazionale) o 404-975-4839 (internazionale) utilizzando il Codice di Accesso 775539. È disponibile un'opzione di pre-registrazione. La trasmissione audio sarà accessibile nella sezione
Iterum Therapeutics plc (Nasdaq: ITRM), una compañía farmacéutica en etapa clínica que desarrolla antibióticos orales e IV de nueva generación, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024, antes de la apertura de los mercados financieros de EE. UU. La compañía llevará a cabo una conferencia telefónica a las 8:30 a.m. ET el mismo día para discutir los resultados y proporcionar una actualización comercial.
Los inversores y partes interesadas pueden acceder a la llamada marcando 833-470-1428 (nacional) o 404-975-4839 (internacional) y utilizando el Código de Acceso 775539. Hay una opción de preinscripción disponible. La transmisión de audio estará accesible en la sección
Iterum Therapeutics plc (Nasdaq: ITRM)는 차세대 경구 및 IV 항생제를 개발하는 임상 단계 제약회사로, 2024년 2분기 재무 결과를 2024년 8월 14일에 미국 금융 시장 개장 전 발표할 계획이라고 발표했습니다. 회사는 같은 날 오전 8시 30분 ET에 결과를 논의하고 비즈니스 업데이트를 제공하기 위한 컨퍼런스 콜을 개최할 예정입니다.
투자자 및 이해관계자는 833-470-1428 (국내) 또는 404-975-4839 (국제)로 전화하여 접근 코드 775539를 사용하여 전화를 접속할 수 있습니다. 사전 등록 옵션이 제공됩니다. 통화 후, Iterum의 웹사이트 www.iterumtx.com의
Iterum Therapeutics plc (Nasdaq: ITRM), une entreprise pharmaceutique en phase clinique développant des antibiotiques oraux et IV de nouvelle génération, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 le 14 août 2024, avant l'ouverture des marchés financiers américains. L'entreprise tiendra une téléconférence à 8h30 ET le même jour pour discuter des résultats et fournir une mise à jour sur les affaires.
Les investisseurs et parties intéressées peuvent accéder à l'appel en composant le 833-470-1428 (national) ou le 404-975-4839 (international) et en utilisant le code d'accès 775539. Une option de préinscription est disponible. Le webinaire audio sera accessible dans la section
Iterum Therapeutics plc (Nasdaq: ITRM), ein pharmazeutisches Unternehmen in der klinischen Phase, das next-generation orale und IV-Antibiotika entwickelt, hat Pläne angekündigt, die Finanzergebnisse für das zweite Quartal 2024 am 14. August 2024, vor der Eröffnung der US-Finanzmärkte, zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate zu geben.
Investoren und Interessierte können an dem Anruf teilnehmen, indem sie 833-470-1428 (national) oder 404-975-4839 (international) wählen und den Zugangscode 775539 verwenden. Eine Voranmeldung ist verfügbar. Der Audio-Webcast wird nach dem Anruf in der Rubrik
- None.
- None.
DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2024 financial results before the open of the U.S. financial markets on Wednesday, August 14, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 775539. To pre-register for this call, please go to the following link: . The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has submitted an NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When will Iterum Therapeutics (ITRM) report its Q2 2024 financial results?
What time is Iterum Therapeutics' (ITRM) Q2 2024 earnings call scheduled for?
How can investors access Iterum Therapeutics' (ITRM) Q2 2024 earnings call?
What is Iterum Therapeutics' (ITRM) focus as a pharmaceutical company?
